secwatch.observer — SEC 8-K summary
======================================

Issuer:     Telomir Pharmaceuticals, Inc. (TELO)
CIK:        0001971532
Form:       8-K
Filed at:   2025-02-25T23:59:59+00:00
Accession:  0001493152-25-008195
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Telomir announces Telomir-1 reverses calcium dysregulation in human cell lines
------------------------------------------------------------------------------

- Telomir-1 fully reversed calcium dysregulation in human keratinocyte (HaCaT) and retinal (ARPE-19) cell lines under oxidative stress.
- Treatment also reduced oxidative stress, preserved cellular integrity, and prevented cell death; untreated cells showed degeneration.
- Telomir is advancing preclinical studies toward human trials for neurodegenerative, retinal, and metabolic diseases.
- The study was conducted in multiple human cell lines, supporting Telomir-1 as a potential first-in-class therapy for aging-related conditions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1971532/000149315225008195/0001493152-25-008195-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1971532/000149315225008195/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-008195

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer